Phase I / II Adaptive Randomized Trial of Vorinostat, Erlotinib and Temozolomide in Adults With Recurrent Glioblastoma Multiforme.

Trial Profile

Phase I / II Adaptive Randomized Trial of Vorinostat, Erlotinib and Temozolomide in Adults With Recurrent Glioblastoma Multiforme.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2014

At a glance

  • Drugs Erlotinib (Primary) ; Temozolomide (Primary) ; Vorinostat (Primary)
  • Indications Astrocytoma; Glioblastoma; Glioma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Jul 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 20 Mar 2014 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
    • 20 Sep 2013 Planned end date changed from 1 Sep 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top